Cognitive Dysfunction in PD: Pathophysiology and Potential Treatments, a Pilot Study
Overview
- Phase
- Phase 4
- Intervention
- Placebo
- Conditions
- Parkinson's Disease
- Sponsor
- Oregon Health and Science University
- Enrollment
- 9
- Locations
- 1
- Primary Endpoint
- Attention Network Effects
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
The purpose of this study is to determine the relationship between attention and quality of life and how rivastigmine and atomoxetine alter attention in non-demented persons with Parkinson's disease (PD).
Detailed Description
Cognitive dysfunction can occur in early stage of Parkinson's disease (PD) and increases as PD progresses. Attention deficits in PD patients with dementia strongly predict the impairment of their daily living activities. Previous studies have shown that atomoxetine improves PD executive dysfunction and rivastigmine improves attention deficits in PD patients with dementia without worsening the motor symptoms. The aim of this study is to examine the effect of atomoxetine and rivastigmine on attention and quality of life in PD patients without disabling cognitive impairment.
Investigators
Jau-Shin Lou
Associate Professor
Oregon Health and Science University
Eligibility Criteria
Inclusion Criteria
- •Clinical diagnosis of Parkinson's disease
- •Respond to levodopa therapy
Exclusion Criteria
- •Psychiatric disorders including anxiety disorders, dissociative disorders, mood disorders, schizophrenia and related disorders, or ADD/ADHD
- •Any clinically unstable disease such as cancer, HIV/AIDS, heart condition, liver disease, kidney or renal failure or others that might require hospitalization
- •Evidence for another neurological disease (history of seizures, Alzheimer disease, multiple sclerosis or other movement disorders);
- •Currently using any of the study drugs;
- •Colorblindness
Arms & Interventions
Placebo
sugar pill
Intervention: Placebo
atomoxetine
Strattera 10-30 mg b.i.d.
Intervention: Strattera
rivastigimine
Exelon 1.5-4.5 mg b.i.d.
Intervention: Exelon
Outcomes
Primary Outcomes
Attention Network Effects
Time Frame: 6 weeks
Secondary Outcomes
- Depression(6 weeks)
- Daytime Sleepiness(6 weeks)
- Quality of Life(6 weeks)
- Fatigue(6 weeks)
- Stroop Color Word Test(6 weeks)